Semb Anne Grete, Ikdahl Eirik, Kerola Anne M, Wibetoe Grunde, Sexton Joseph, Crowson Cynthia S, van Riel Piet, Kitas George, Graham Ian, Rollefstad Silvia
Preventive Cardio-Rheuma Clinic, Center for treatment of Rheumatic and Musculoskeletal Diseases [REMEDY], Diakonhjemmet Hospital, Oslo, Norway.
Center for treatment of Rheumatic and Musculoskeletal Diseases [REMEDY], Diakonhjemmet Hospital, Oslo, Norway.
Mediterr J Rheumatol. 2022 Jun 30;33(2):201-217. doi: 10.31138/mjr.33.2.201. eCollection 2022 Jun.
Rheumatoid arthritis (RA) patients are at a high risk of atherosclerotic cardiovascular disease (ASCVD). This implies a need for meticulous CVD risk factor recording and control.
The aim was to evaluate the international prevalence of ASCVD in RA patients and to audit the prevalence and control of CVD risk factors.
A rvey of cardiovascular disease isk actors in patients with heumatoid rthritis (SURF-RA) was performed at 53 centres in 19 countries in three continents between 2014 and 2019. CVD risk factors, medication, and physical and laboratory measurements were recorded. CVD risk was estimated using the ESC's SCORE system.
Among 14503 RA patients in Western (n=8493) and Central and Eastern (n=923) Europe, Mexico (n=407), North America (n=4030) and Asia (n=650) (mean age 59.9 years, 74.5% female), ASCVD was present in 15%, varying from 2.5% in Mexico to 21% in Central and Eastern Europe. Sixty-two percent reported hypertension and 63% had a LDL-c of > 2.5 mmol/L. Mean BMI was 27.4 kg/m in the total cohort, highest in North America (29.7 kg/m), and lowest in Asia (23.8 kg/m). A sixth of patients were current smokers, and 13% had diabetes mellitus. Approximately 45% had an estimated high or very high risk of fatal CVD according to SCORE algorithm, and ¾ of patients had only ≤4/6 CVD risk factors at recommended target.
Among RA patients across three continents, established CVD and CVD risk factors are common, although geographical variation exists. Furthermore, CVD risk factors often remain inadequately controlled.
类风湿关节炎(RA)患者患动脉粥样硬化性心血管疾病(ASCVD)的风险很高。这意味着需要细致地记录和控制心血管疾病风险因素。
旨在评估RA患者中ASCVD的国际患病率,并审查心血管疾病风险因素的患病率及控制情况。
2014年至2019年间,在三大洲19个国家的53个中心开展了一项类风湿关节炎患者心血管疾病风险因素调查(SURF-RA)。记录了心血管疾病风险因素、用药情况以及体格和实验室测量结果。使用欧洲心脏病学会(ESC)的SCORE系统评估心血管疾病风险。
在来自西欧(n = 8493)、中东欧(n = 923)、墨西哥(n = 407)、北美(n = 4030)和亚洲(n = 650)的14503例RA患者中(平均年龄59.9岁,74.5%为女性),ASCVD的患病率为15%,从墨西哥的2.5%到中东欧的21%不等。62%的患者报告患有高血压,63%的患者低密度脂蛋白胆固醇(LDL-c)>2.5 mmol/L。整个队列的平均体重指数(BMI)为27.4 kg/m²,北美最高(29.7 kg/m²),亚洲最低(23.8 kg/m²)。六分之一的患者为当前吸烟者,13%的患者患有糖尿病。根据SCORE算法,约45%的患者估计有发生致命性心血管疾病的高风险或极高风险,四分之三的患者仅存在≤4/6项达到推荐目标的心血管疾病风险因素。
在三大洲的RA患者中,尽管存在地域差异,但确诊的心血管疾病和心血管疾病风险因素很常见。此外,心血管疾病风险因素往往仍未得到充分控制。